Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Handling Drug Price Spikes: A Sad Place To Be

This article was originally published in Scrip

Executive Summary

When Valeant Pharmaceuticals International Inc. suddenly raised the prices of two critical drugs in the hospital setting, Nitropress (sodium nitroprusside) and Isuprel (isoprenaline), facilities had to find a way to deal with ensuring they had those vital medicines available, but doing so without breaking the bank.

You may also be interested in...



Marathon's High-Priced Window May Not Stay Open Long

Ongoing trial is intended to compare the newly approved steroid Emflaza with prednisone in DMD for efficacy and safety.

Excessive Drug Pricing: What It Is, And What It Isn't

It's difficult to know exactly how to define "excessive" or "unfair" pricing where pharmaceutical products are concerned, and many factors have to be taken into account. Even the EU Commission and competition authorities may be reluctant to pursue cases of alleged price gouging, lawyer David Hull told Informa's recent EU Pharma Law Forum in Brussels.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Topics

UsernamePublicRestriction

Register

SC063906

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel